NASDAQ · ONCT
Oncternal Therapeutics, Inc.
$0.53-$0.17 (-24.12%)
Oncternal Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.04% below the high.
Loading market information…
NASDAQ · CWBR · USD
Stock price, earnings
Quote as of Jan 17, 2025, 12:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CohBar, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow CohBar, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.53-$0.17 (-24.12%)
Oncternal Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.04% below the high.
$0.03$0.00 (0.0%)
Cassava Sciences, Inc. Warrant’s quoted price sits in the lower half of its reported 52-week range, 99.73% below the high.
$0.38-$0.01 (-1.56%)
NeuBase Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.49% below the high.
$0.34+$0.00 (+0.74%)
Timber Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.89% below the high.
$0.30+$0.30 (+100.0%)
Altamira Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.85% below the high.
$0.32-$0.17 (-34.28%)
InVivo Therapeutics Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 86.64% below the high.
$0.04-$0.02 (-27.27%)
Impel Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.05% below the high.
$0.07-$0.01 (-6.68%)
Bellicum Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.29% below the high.
